Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 15/20 | 0.66 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7542568 | 0.86 | PTGS2 (0.49) | PTGS2PTGS1MMP1MMP2MMP9 | |
| SCHEMBL7100203 | 0.82 | GAA (0.64) | SMN1; SMN2GAAALDH1A1LMNAL3MBTL1 | |
| SCHEMBL8652481 | 0.80 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL8652822 | 0.78 | PTGS2 (0.72) | PTGS2PTGS1CA1CA2 | |
| SCHEMBL7540369 | 0.78 | PTGS2 (0.49) | PTGS2PTGS1MMP1MMP2MMP9 | |
| SCHEMBL7538559 | 0.77 | PTGS2 (0.46) | PTGS2PTGS1MMP1MMP2MMP9 | |
| SCHEMBL7540175 | 0.77 | PTGS2 (0.50) | PTGS2PTGS1MMP1MMP2MMP9 | |
| SCHEMBL5071852 | 0.74 | PTGS2 (0.69) | PTGS2PTGS1SMN1; SMN2GAA | |
| SCHEMBL7543918 | 0.74 | PTGS2 (0.51) | PTGS2PTGS1 | |
| SCHEMBL8266062 | 0.71 | MAPK14 (0.62) | PTGS2PTGS1LMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, FPR1, PTGES2 | PTGS2 5/4885PTGS1 4/4885SMN1; SMN2 2004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.